Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7982398 | 0.92 | UTS2R (0.35) | CETPPTGER1GAALMNAKMT2A | |
| SCHEMBL7986056 | 0.90 | PTGER1 (0.37) | CETPPTGER1GAALMNA | |
| SCHEMBL7986054 | 0.88 | PTGER1 (0.34) | CETPPTGER1GAALMNA | |
| SCHEMBL7572801 | 0.86 | F2 (0.38) | CETPPTGER1GAAKMT2A | |
| SCHEMBL7982392 | 0.86 | TRPV1 (0.35) | CETPPTGER1GAA | |
| SCHEMBL7986061 | 0.85 | PTGER1 (0.35) | CETPPTGER1 | |
| SCHEMBL7982400 | 0.84 | F2 (0.39) | CETPPTGER1 | |
| SCHEMBL7209116 | 0.84 | GAA (0.38) | CETPPTGER1GAAKMT2ANOTUM | |
| SCHEMBL8058096 | 0.84 | CETP (0.38) | CETPPTGER1GAAKMT2ANOTUM | |
| SCHEMBL8047891 | 0.83 | GAA (0.36) | CETPPTGER1GAALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6297241-B1 | TREATMENT OF DISORDERS WHICH ARE RESPONSIVE TO THE OPENING OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS. | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | claimed |
| US-6297241-B1 | TREATMENT OF DISORDERS WHICH ARE RESPONSIVE TO THE OPENING OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS. | BRISTOL-MYERS SQUIBB COMPANY | 2001-10-02 | — | — | US | disclosed |